SOPHiA DDM™ Platform Measurable Residual Disease (MRD)

SOPHiA DDM™ for Measurable Residual Disease

Go beyond complete response with targeted NGS MRD analysis

Identify even the smallest traces of cancer cells by combining the power of next-generation sequencing (NGS) and the advanced analytical capabilities of the SOPHiA DDM™ Platform.

Overview

Confidently detect the last cancer cells

More than 50% of Acute Myeloid Leukemia (AML) patients relapse within three years after achieving complete remission.1 The SOPHiA DDM™ Residual Acute Myeloid (RAM) Solution utilizes targeted NGS analysis to accurately detect variants down to 0.01% variant allele frequency (VAF) for key genes linked to AML.

Get the complete MRD story

Simultaneously assess 23 ELN guideline-recommended genes to identify and monitor AML-associated mutations in a single sample.

The SOPHiA DDM™ RAM Solution utilizes a decentralized, platform-agnostic workflow powered by advanced analytics, enabling clinical research in MRD and accelerating breakthrough discoveries.

1. www.leukameiacare.org.uk

Key Features

Aim for the right targets in MRD detection

Empower robust decision-making with accurate detection of key AML genomic biomarkers, streamlined variant interpretation, and simplified longitudinal monitoring.

Increase sensitivity

Leverage our proprietary CUMIN™ molecular adaptor technology for ultrasensitive variant detection with a limit of detection (LoD) down to 0.01% VAF.

Boost efficiency

Enhance productivity with NextSeq® and NovaSeq™ compatibility, and automated workflows on leading liquid handling robots.

Analyze tumor evolution

Utilize a dedicated interface for longitudinal variant monitoring to visualize the mutational landscape and its evolution over time.

Workflow

See what other tests might miss with NGS

Streamline your sample-to-report MRD workflow with solutions designed to enhance genomic profiling and monitoring of residual disease.

Flexible and scalable library preparation

Use one universal, automatable protocol for sequencing on NextSeq and NovaSeq systems.

Advanced analytical performance

Rely on multiple MRD markers to increase the gap between the signal and the noise.

Longitudinal monitoring

Leverage a user-friendly interface that simplifies tracking of AML dynamics over time.

Streamlined variant interpretation

Quickly assess variants with enhanced tertiary analysis and community-driven insights.

Analytics

Enhance your MRD analysis

Expand your MRD detection capabilities with the power of NGS and the advanced analytics of the SOPHiA DDM™ Platform.

Precise molecular barcoding
Sensitive SNV and Indel detection
Reliable MRD signal measurement

SOPHiA DDM™ enables sensitive detection of MRD markers at allele frequencies as low as 0.01% with excellent sensitivity. By incorporating our proprietary CUMIN™ unique molecular identifier (UMI) technology into sample preparation and leveraging our bioinformatic expertise, errors introduced during library preparation, target enrichment, or sequencing can be filtered out and true variant alleles identified. Moreover, precise molecule counting allows you to reliably measure the MRD signal.

Our sophisticated SNV and Indel calling algorithm implements relevant analytical modules that are tailored to reduce noise linked to sample type, sequencer, and library preparation. Owing to probabilistic, molecule-based signal estimation, molecular signal and noise measurements for each individual MRD marker are provided.

MRD Score provides a measure of the MRD signal reliability by comparing the signal of one or more selected MRD markers to the expected noise levels at the genomic position of each marker. A score of 50 or more, on a scale of 0-100, means that the signal is significantly higher than the expected background noise.

Unlock MRD insights over time

SOPHiA DDM™ with its dedicated OncoPortal™ Mutation Tracker add-on streamlines longitudinal comparisons by consolidating various SOPHiA DDM™ RAM Solution time-point results into a single analysis. This add-on module enables to track changes in variants and adapt thresholds to discern variant presence or absence. 

SOPHiA DDM™ RAM Solution

Stay ahead of the curve with continuous MRD monitoring

This longitudinal interface represents the solution we’ve been seeking to unite our oncologists in embracing broader adoption of NGS It’s the missing piece that unlocks new frontiers in personalized, data-driven medicine.”

Dr. Christophe Marzac
Head of the Hematology Gustave Roussy Institute

Resources

Featured Resources

SOPHiA DDM™ RAM Solution

SOPHiA DDM™ RAM Solution

SOPHiA DDM™ RAM Solution

Aim for the right targets in measurable residual disease detection

';